Laden…
(2R)-1-(4-bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine
Bromo-DragonFLY is a substance from the class of benzodifurans. Further information will follow after enrichment.
Class
Psychedelika
Pharmacological context
Mechanism
5-HT2A agonist
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
Interpret risks carefully
Condensed from structured notes
Translation in progress
The German version has more complete content. This English page is being expanded; safety-critical risk and interaction sections may still appear while translation continues.
Receptor Targets
Mechanism of Action
Bromo-DragonFLY acts through the following pharmacological mechanisms:
Designations
IUPAC: [(1R)-2-(4-bromofuro[2,3-f]benzofuran-8-yl)-1-methyl-ethyl]amine
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Receptor Profile
Der 5-HT2A-Rezeptor ist ein Serotonin-Rezeptor der Klasse Gq-gekoppelter GPCRs. Er ist der primäre molekulare Angriffspunkt klassischer Psychedelika und spielt eine Rolle bei Kognition und Wahrnehmung.
Der 5-HT1A-Rezeptor ist ein Gi/Go-gekoppelter Serotoninrezeptor, der als Autorezeptor auf serotonergen Neuronen und als Heterorezeptor in verschiedenen Hirnregionen vorkommt. Er moduliert Angst, Stimmung und Kognition.
Der Serotonintransporter (SERT/5-HTT) ist ein Natrium-abhängiger Monoamintransporter, der Serotonin aus dem synaptischen Spalt zurück in die präsynaptische Zelle transportiert. Er ist das primäre Ziel von SSRI und MDMA.
Der Dopamintransporter (DAT) ist ein Natrium-abhängiger Monoamintransporter, der Dopamin aus dem synaptischen Spalt entfernt. Er ist ein zentrales Ziel von Stimulants und spielt eine Schlüsselrolle im Belohnungssystem.
Der 5-HT2C-Rezeptor ist ein Gq/11-gekoppelter Serotoninrezeptor, der an der Regulation von Appetit, Stimmung und Angst beteiligt ist. Er wird von verschiedenen Psychedelika als sekundäres Ziel aktiviert und moduliert dopaminerge Signalwege.
Substance Fingerprint
Pharmacological profile based on receptor binding, mechanism of action, and substance class.
Synapedia Evidence
Effects & Pharmacology translation in progress
English prose is being expanded. The German version currently has more detail.
Reported range 200–400 µg
Total duration 12–24 hours
Oral
| Tier | Dosage |
|---|---|
| Light | 100 µg |
| Reported | 200–400 µg |
| Strong | 500 µg+ |
Oral
Onset
1–2 hours
Peak
4–6 hours
Total duration
12–24 hours
After effects
up - 24 hours
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Die Risiken sind nicht vollständig bekannt, da die Substanz wenig erforscht ist.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.